Therigy, a company that pioneered patient-focused specialty therapy management, recently announced a strategic partnership with EPI-Q Inc. to expand research on specialty pharmacy outcomes.
“As the specialty pharmacy industry and the health care industry as a whole continue to make the revolutionary shift from volume-based to value-based care, real-world evidence becomes increasingly important for ensuring positive patient outcomes and shaping the future of the industry,” Therigy said in a statement.
Therigy noted that EPI-Q brings more than 20 years of experience to the research table, along with a full team of epidemiologists and research scientists, health policy analysts, and clinicians. Together, the companies will investigate specialty pharmacy drugs in real-world settings by examining their utilization, effectiveness, and clinical outcomes.
“Therigy’s comprehensive data, coupled with EPI-Q’s dedication to scientific research and analysis, will open doors for pharmacies, manufacturers, hospital systems, payers, and patients alike,” Dr. Russel Allinson, Therigy’s CEO and chief clinical officer, said in a statement. “This partnership will facilitate further insights into how critical drugs are performing, and how this research can be applied to improving specialty pharmacy patient outcomes over the long term.”
Alerts Sign-up